+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Red Biotechnology Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 172 Pages
  • November 2023
  • Region: Global
  • Expert Market Research
  • ID: 5921382
According to the report, the global red biotechnology market is projected to grow at a CAGR of 6.20% between 2024 and 2032 reaching a value of approximate USD 600.76 billion by 2032. Aided by the escalating demand for therapeutic solutions, innovative drugs, and genetic engineering, the market is expected to grow significantly by 2032.

Red biotechnology, often synonymous with medical biotechnology, primarily focuses on the use of organisms to improve health outcomes, devise novel pharmaceuticals, and explore regenerative medicines. It spans across a plethora of areas including diagnostics, drug discovery, gene therapy, and personalised medicine, leveraging cellular and biomolecular processes to advance medical solutions and tools.

The unyielding march of diseases and health complications, particularly chronic illnesses, is a predominant catalyst propelling the red biotechnology market growth. As the global population grapples with medical challenges ranging from cancer, diabetes, to neurodegenerative disorders, the medical fraternity turns to red biotechnology for groundbreaking therapies and solutions.

Personalised medicine, a paradigm shift in medical treatment, tailor-fits therapeutic solutions based on individual genetic make-up. It underscores a transformative approach, pivoting from a 'one-size-fits-all' model to bespoke treatment plans. The advent of genomic sequencing and the decreasing costs associated with it have catapulted this segment, solidifying its place within the red biotechnology realm.

The accelerating pace of genetic engineering and its convergence with therapeutic solutions also influences the red biotechnology market outlook. Techniques such as CRISPR-Cas9 have revolutionised the way genetic disorders are approached, offering potential cures and treatments that were previously deemed elusive. Moreover, advancements in regenerative medicine, especially stem cell research, hold the promise of reconstructing damaged tissues, organs, and even revolutionising transplants.

Another salient driver for the red biotechnology market is the collaborative efforts of academic institutions, research facilities, and pharmaceutical giants. This synergy fosters an environment of innovation, expediting the translational research from labs to clinical applications. Additionally, governmental backing in the form of funding, subsidies, and favourable regulatory frameworks in many regions further accentuates market growth. In regional terms, North America accounts for a significant portion of the red biotechnology market share, driven by the advancements taking place in the bio-tech sector.

Market Segmentation

The market can be divided based on application, end-use, and region.

Market Breakup by Application

  • Biopharmaceutical Production
  • Gene Therapy
  • Pharmacogenomics
  • Genetic Testing

Market Breakup by End-Use

  • Pharmaceutical Industry
  • CMO & CRO
  • Research Institutes
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global red biotechnology market. Some of the major players explored in the report are as follows:
  • Pfizer Inc.
  • Biogen Inc.
  • Amgen Inc.
  • Astrazeneca Plc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KGaA
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • Others

Table of Contents

1 Preface2 Report Coverage - Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Red Biotechnology Market Analysis
8.1 Key Industry Highlights
8.2 Global Red Biotechnology Historical Market (2018-2023)
8.3 Global Red Biotechnology Market Forecast (2024-2032)
8.4 Global Red Biotechnology Market by Application
8.4.1 Biopharmaceutical Production
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Gene Therapy
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Pharmacogenomics
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Genetic Testing
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.5 Global Red Biotechnology Market by End-use
8.5.1 Pharmaceutical Industry
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 CMO & CRO
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Research Institutes
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Others
8.6 Global Red Biotechnology Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Red Biotechnology Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Red Biotechnology Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Red Biotechnology Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Red Biotechnology Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Red Biotechnology Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter's Five Forces Analysis
14.2.1 Supplier's Power
14.2.2 Buyer's Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Pfizer Inc.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Biogen Inc.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Amgen Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Astrazeneca Plc.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Gilead Sciences, Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 F. Hoffmann-La Roche, Ltd.
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Merck KGaA
16.2.7.1 Company Overview
16.2.7.2 Product Portfolio
16.2.7.3 Demographic Reach and Achievements
16.2.7.4 Certifications
16.2.8 Bristol-Myers Squibb Company
16.2.8.1 Company Overview
16.2.8.2 Product Portfolio
16.2.8.3 Demographic Reach and Achievements
16.2.8.4 Certifications
16.2.9 Regeneron Pharmaceuticals Inc.
16.2.9.1 Company Overview
16.2.9.2 Product Portfolio
16.2.9.3 Demographic Reach and Achievements
16.2.9.4 Certifications
16.2.10 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Red Biotechnology Market: Key Industry Highlights, 2018 and 2032
2. Global Red Biotechnology Historical Market: Breakup by Application (USD Million), 2018-2023
3. Global Red Biotechnology Market Forecast: Breakup by Application (USD Million), 2024-2032
4. Global Red Biotechnology Historical Market: Breakup by End-use (USD Million), 2018-2023
5. Global Red Biotechnology Market Forecast: Breakup by End-use (USD Million), 2024-2032
6. Global Red Biotechnology Historical Market: Breakup by Region (USD Million), 2018-2023
7. Global Red Biotechnology Market Forecast: Breakup by Region (USD Million), 2024-2032
8. North America Red Biotechnology Historical Market: Breakup by Country (USD Million), 2018-2023
9. North America Red Biotechnology Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Europe Red Biotechnology Historical Market: Breakup by Country (USD Million), 2018-2023
11. Europe Red Biotechnology Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Asia Pacific Red Biotechnology Historical Market: Breakup by Country (USD Million), 2018-2023
13. Asia Pacific Red Biotechnology Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Latin America Red Biotechnology Historical Market: Breakup by Country (USD Million), 2018-2023
15. Latin America Red Biotechnology Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Middle East and Africa Red Biotechnology Historical Market: Breakup by Country (USD Million), 2018-2023
17. Middle East and Africa Red Biotechnology Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Global Red Biotechnology Market Structure

Companies Mentioned

  • Pfizer Inc. (NYSE: PFE)
  • Biogen Inc. (NASDAQ: BIIB)
  • Amgen Inc. (NASDAQ: AMGN)
  • AstraZeneca Plc. (LON: AZN)
  • Gilead Sciences Inc. (NASDAQ: GILD)
  • F. Hoffmann-La Roche ltd (SWX: ROG)
  • Merck KGaA (ETR: MRK)
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Methodology

Loading
LOADING...

Table Information